Response

Brisson, Marc; Drolet, Mélanie; Boily, Marie‐Claude; Malagón, Talía; Franco, Eduardo L.; Laprise, J.-F.; Velde, N. van de; Mayrand, M.-H.; Kliewer, Erich V.; Coutlee, F.

doi:10.1093/jnci/djt056

Cited by 4 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 1 provides an overview of the data sources and key steps of the modelling framework described in the following sections. We synthesised the long-term population-wide impact of HPV vaccination on cervical cancer incidence by age and time predicted by three published transmission dynamic models: (i) the UK Health Security Agency (HSA) model, 1 a compartmental dynamic model set in the UK [36]; (ii) the HPV-ADVISE model, an individual-based dynamic model set in Uganda, Nigeria, India, Vietnam [27,37], and Canada [38,39]; and (iii) the Harvard model, a hybrid model that links two individual-based models, set in the US, Uganda, El Salvador, and Nicaragua [14,[40][41][42]. In total, we combined results from 10 model-country scenarios.…”

Section: Methodsmentioning

confidence: 99%

Global Impact and Cost-Effectiveness of One-Dose Versus Two-Dose Human Papillomavirus Vaccination Schedules: A Comparative Modelling Analysis

et al. 2021

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Global Impact and Cost-Effectiveness of One-Dose Versus Two-Dose Human Papillomavirus Vaccination Schedules: A Comparative Modelling Analysis

et al. 2021

View full text Add to dashboard Cite

“…Figure 1 provides an overview of the data sources and key steps of the modelling framework described in the following sections. We synthesised the long-term population-wide impact of HPV vaccination on cervical cancer incidence by age and time predicted by three published transmission dynamic models: (i) the UK Health Security Agency (HSA) model, 1 a compartmental dynamic model set in the UK [ 36 ]; (ii) the HPV-ADVISE model, an individual-based dynamic model set in Uganda, Nigeria, India, Vietnam [ 27 , 37 ], and Canada [ 38 , 39 ]; and (iii) the Harvard model, a hybrid model that links two individual-based models, set in the US, Uganda, El Salvador, and Nicaragua [ 14 , 40 – 42 ]. In total, we combined results from 10 model-country scenarios.…”

Section: Methodsmentioning

confidence: 99%

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

Prem,

Choi,

Bénard

et al. 2023

BMC Med

View full text Add to dashboard Cite

Background To eliminate cervical cancer as a public health problem, the World Health Organization had recommended routine vaccination of adolescent girls with two doses of the human papillomavirus (HPV) vaccine before sexual initiation. However, many countries have yet to implement HPV vaccination because of financial or logistical barriers to delivering two doses outside the infant immunisation programme. Methods Using three independent HPV transmission models, we estimated the long-term health benefits and cost-effectiveness of one-dose versus two-dose HPV vaccination, in 188 countries, under scenarios in which one dose of the vaccine gives either a shorter duration of full protection (20 or 30 years) or lifelong protection but lower vaccine efficacy (e.g. 80%) compared to two doses. We simulated routine vaccination with the 9-valent HPV vaccine in 10-year-old girls at 80% coverage for the years 2021–2120, with a 1-year catch-up campaign up to age 14 at 80% coverage in the first year of the programme. Results Over the years 2021–2120, one-dose vaccination at 80% coverage was projected to avert 115.2 million (range of medians: 85.1–130.4) and 146.8 million (114.1–161.6) cervical cancers assuming one dose of the vaccine confers 20 and 30 years of protection, respectively. Should one dose of the vaccine provide lifelong protection at 80% vaccine efficacy, 147.8 million (140.6–169.7) cervical cancer cases could be prevented. If protection wanes after 20 years, 65 to 889 additional girls would need to be vaccinated with the second dose to prevent one cervical cancer, depending on the epidemiological profiles of the country. Across all income groups, the threshold cost for the second dose was low: from 1.59 (0.14–3.82) USD in low-income countries to 44.83 (3.75–85.64) USD in high-income countries, assuming one dose confers 30-year protection. Conclusions Results were consistent across the three independent models and suggest that one-dose vaccination has similar health benefits to a two-dose programme while simplifying vaccine delivery, reducing costs, and alleviating vaccine supply constraints. The second dose may become cost-effective if there is a shorter duration of protection from one dose, cheaper vaccine and vaccination delivery strategies, and high burden of cervical cancer.

show abstract

“…Fig 1 provides an overview of the data sources and key steps of the modelling framework described in the following sections. We synthesised the long-term population-wide impact of HPV vaccination on cervical cancer incidence by age and time predicted by three published transmission dynamic models: (i) the Public Health England (PHE) model, a compartmental dynamic model set in the UK (32); (ii) the HPV-ADVISE model, an individual-based dynamic model set in Uganda, Nigeria, India, Vietnam (27,33), and Canada (34,35); and (iii) the Harvard model, a hybrid model that links two individual-based models, set in the US, Uganda, El Salvador, and Nicaragua (14,36). In total, we combined results from 10 model-country scenarios.…”

Section: Methodsmentioning

confidence: 99%

“…The minimum duration of protection in the waning scenarios for one-dose reflects the availability of over 10 years of data from various studies-ESCUDDO trial (28,29), IARC India post-randomisation analysis (30)-that do not show any evidence of waning of either clinical or immunological protection (31). (27,33), and Canada (34,35); and (iii) the Harvard model, a hybrid model that links two individual-based models, set in the US, Uganda, El Salvador, and Nicaragua (14,36). In total, we combined results from 10 model-country scenarios.…”

Section: Methodsmentioning

confidence: 99%

“…All protect against the two most carcinogenic HPV types, 16 and 18, which are responsible for 70% of cervical cancer cases globally (6)(7)(8). Some additionally protect against HPV types 6 and 11, which do not cause cancer but are responsible for most cases of anogenital warts, and against other high-risk types such as HPV 31,33,45,52, and 58 (either directly or through cross-protection), which have been linked to a further 20% of cervical cancer cases (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

Prem

Choi

eacutenard

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To eliminate cervical cancer as a public health problem, WHO currently recommends routine vaccination of adolescent girls with two doses of the human papillomavirus (HPV) vaccine before sexual debut. However, many countries have yet to implement this because of financial or logistical barriers to delivering two doses outside the infant immunisation programme. Methods: Using three independent HPV transmission models, we estimated the long-term health benefits and cost-effectiveness of one-dose versus two-dose HPV vaccination, in 192 countries, assuming that one dose of the vaccine gives either a shorter duration of full protection (20 or 30 years) or lifelong protection but lower vaccine efficacy (e.g., 80%) compared to two doses. We simulated routine vaccination with the 9-valent HPV vaccine in 10-year-old girls at 80% coverage for the years 2021-2120, with a one-year catch-up of 80% 11-14-year-old girls on the first year of the programme. Findings: Over the next century, one-dose vaccination at 80% coverage could avert 64 million (80%UI 62.2-64.8) and 66.6 million (80%UI 63.4-69.1) cervical cancer cases should one dose of the vaccine confer 20 and 30 years of protection, respectively. Should one dose of the vaccine provide lifelong protection at 80% vaccine efficacy, 68.4 million (80%UI 63.8-69.4) cervical cancer cases could be prevented. Across all country income groups, two-dose schedules conferring lifelong protection would avert only slightly more cases (2.1-8.7 million) than the one-dose scenarios explored. Around 330 to 5230 additional girls need to be vaccinated with the second dose to prevent one cervical cancer case, depending on the epidemiological profiles of the country. Interpretation: Results were consistent across the three independent models and suggest that one-dose vaccination has similar health benefits to a two-dose programme while simplifying vaccine delivery, reducing costs and alleviating vaccine supply constraints. Funding: Bill & Melinda Gates Foundation

show abstract

Response

Cited by 4 publications

References 2 publications

Global Impact and Cost-Effectiveness of One-Dose Versus Two-Dose Human Papillomavirus Vaccination Schedules: A Comparative Modelling Analysis

Global Impact and Cost-Effectiveness of One-Dose Versus Two-Dose Human Papillomavirus Vaccination Schedules: A Comparative Modelling Analysis

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

Contact Info

Product

Resources

About